Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis
Background: Prevalence and incidence rates of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) are required to determine the impact of CIDP on society. We aimed to estimate the prevalence and incidence of CIDP worldwide and to determine the effect of diagnostic criteria on prevalence...
Saved in:
| Published in: | Neuroepidemiology Vol. 52; no. 3-4; pp. 161 - 172 |
|---|---|
| Main Authors: | , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Basel, Switzerland
01.01.2019
|
| Subjects: | |
| ISSN: | 0251-5350, 1423-0208, 1423-0208 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Background: Prevalence and incidence rates of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) are required to determine the impact of CIDP on society. We aimed to estimate the prevalence and incidence of CIDP worldwide and to determine the effect of diagnostic criteria on prevalence and incidence. Method: A systematic review was conducted for all published incidence and prevalence studies on CIDP until May 18, 2017. Methodological quality was assessed using the Methodological Evaluation of Observational Research checklist. We performed a random effect meta-analysis to estimate pooled prevalence and incidence rates. Results: Of the 907 studies, 11 were included in the systematic review, 5 in the meta-analysis of incidence (818 cases; 220,513,514 person-years) and 9 in the meta-analysis of prevalence (3,160 cases; 160,765,325 population). These studies had a moderate quality. The pooled crude incidence rate was 0.33 per 100,000 person-years (95% CI 0.21–0.53; I 2 = 95.7%) and the pooled prevalence rate was 2.81 per 100,000 (95% CI 1.58–4.39; I 2 = 99.1%). Substantial heterogeneity in incidence and prevalence across studies seems to be partly explained by using different diagnostic criteria. Conclusion: These findings provide a starting point to estimate the social burden of CIDP and demonstrate the need to reach consensus on diagnostic criteria for CIDP. |
|---|---|
| AbstractList | Prevalence and incidence rates of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) are required to determine the impact of CIDP on society. We aimed to estimate the prevalence and incidence of CIDP worldwide and to determine the effect of diagnostic criteria on prevalence and incidence.BACKGROUNDPrevalence and incidence rates of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) are required to determine the impact of CIDP on society. We aimed to estimate the prevalence and incidence of CIDP worldwide and to determine the effect of diagnostic criteria on prevalence and incidence.A systematic review was conducted for all published incidence and prevalence studies on CIDP until May 18, 2017. Methodological quality was assessed using the Methodological Evaluation of Observational Research checklist. We performed a random effect meta-analysis to estimate pooled prevalence and incidence rates.METHODA systematic review was conducted for all published incidence and prevalence studies on CIDP until May 18, 2017. Methodological quality was assessed using the Methodological Evaluation of Observational Research checklist. We performed a random effect meta-analysis to estimate pooled prevalence and incidence rates.Of the 907 studies, 11 were included in the systematic review, 5 in the meta-analysis of incidence (818 cases; 220,513,514 person-years) and 9 in the meta-analysis of prevalence (3,160 cases; 160,765,325 population). These studies had a moderate quality. The pooled crude incidence rate was 0.33 per 100,000 person-years (95% CI 0.21-0.53; I2 = 95.7%) and the pooled prevalence rate was 2.81 per 100,000 (95% CI 1.58-4.39; I2 = 99.1%). Substantial heterogeneity in incidence and prevalence across studies seems to be partly explained by using different diagnostic criteria.RESULTSOf the 907 studies, 11 were included in the systematic review, 5 in the meta-analysis of incidence (818 cases; 220,513,514 person-years) and 9 in the meta-analysis of prevalence (3,160 cases; 160,765,325 population). These studies had a moderate quality. The pooled crude incidence rate was 0.33 per 100,000 person-years (95% CI 0.21-0.53; I2 = 95.7%) and the pooled prevalence rate was 2.81 per 100,000 (95% CI 1.58-4.39; I2 = 99.1%). Substantial heterogeneity in incidence and prevalence across studies seems to be partly explained by using different diagnostic criteria.These findings provide a starting point to estimate the social burden of CIDP and demonstrate the need to reach consensus on diagnostic criteria for CIDP.CONCLUSIONThese findings provide a starting point to estimate the social burden of CIDP and demonstrate the need to reach consensus on diagnostic criteria for CIDP. Prevalence and incidence rates of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) are required to determine the impact of CIDP on society. We aimed to estimate the prevalence and incidence of CIDP worldwide and to determine the effect of diagnostic criteria on prevalence and incidence. A systematic review was conducted for all published incidence and prevalence studies on CIDP until May 18, 2017. Methodological quality was assessed using the Methodological Evaluation of Observational Research checklist. We performed a random effect meta-analysis to estimate pooled prevalence and incidence rates. Of the 907 studies, 11 were included in the systematic review, 5 in the meta-analysis of incidence (818 cases; 220,513,514 person-years) and 9 in the meta-analysis of prevalence (3,160 cases; 160,765,325 population). These studies had a moderate quality. The pooled crude incidence rate was 0.33 per 100,000 person-years (95% CI 0.21-0.53; I2 = 95.7%) and the pooled prevalence rate was 2.81 per 100,000 (95% CI 1.58-4.39; I2 = 99.1%). Substantial heterogeneity in incidence and prevalence across studies seems to be partly explained by using different diagnostic criteria. These findings provide a starting point to estimate the social burden of CIDP and demonstrate the need to reach consensus on diagnostic criteria for CIDP. Background: Prevalence and incidence rates of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) are required to determine the impact of CIDP on society. We aimed to estimate the prevalence and incidence of CIDP worldwide and to determine the effect of diagnostic criteria on prevalence and incidence. Method: A systematic review was conducted for all published incidence and prevalence studies on CIDP until May 18, 2017. Methodological quality was assessed using the Methodological Evaluation of Observational Research checklist. We performed a random effect meta-analysis to estimate pooled prevalence and incidence rates. Results: Of the 907 studies, 11 were included in the systematic review, 5 in the meta-analysis of incidence (818 cases; 220,513,514 person-years) and 9 in the meta-analysis of prevalence (3,160 cases; 160,765,325 population). These studies had a moderate quality. The pooled crude incidence rate was 0.33 per 100,000 person-years (95% CI 0.21–0.53; I 2 = 95.7%) and the pooled prevalence rate was 2.81 per 100,000 (95% CI 1.58–4.39; I 2 = 99.1%). Substantial heterogeneity in incidence and prevalence across studies seems to be partly explained by using different diagnostic criteria. Conclusion: These findings provide a starting point to estimate the social burden of CIDP and demonstrate the need to reach consensus on diagnostic criteria for CIDP. |
| Author | Nieboer, Daan Jacobs, Bart C. Broers, Merel C. Lingsma, Hester F. Bunschoten, Carina |
| Author_xml | – sequence: 1 givenname: Merel C. surname: Broers fullname: Broers, Merel C. email: m.broers@erasmusmc.nl – sequence: 2 givenname: Carina surname: Bunschoten fullname: Bunschoten, Carina – sequence: 3 givenname: Daan surname: Nieboer fullname: Nieboer, Daan – sequence: 4 givenname: Hester F. surname: Lingsma fullname: Lingsma, Hester F. – sequence: 5 givenname: Bart C. surname: Jacobs fullname: Jacobs, Bart C. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30669140$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkUlPwzAQhS1UBGU5cEcoEhcuAduxk5hb1bJUKotYzpHrjFuD4xQ7AUXixxNR4MRpNHrfmxm92UEDVztA6IDgU0K4OMMYM8GoIBtoSBhNYkxxPkBDTDmJecLxNtoJ4QXjHs7FFtpOcJoKwvAQfU6dMiU4BZF0ZXTv4V3a77bW0Xjpa2dUNHXayqqSTe27aAJVB9Y42Ri3iO5r23lZGtXa_qbW1yvZLLvzaBQ9dqGB3tP7H-DdwMf3ghtoZDxy0nbBhD20qaUNsP9Td9Hz5cXT-Dqe3V1Nx6NZrDilTSyYokTP8ySTjOZ0LkSJNSsTrrKMEa10yiRnOQOVZpBrRSlhnAAvGeQpSyHZRSfruStfv7UQmqIyQYG10kHdhoKSTDCc9aH16NEP2s4rKIuVN5X0XfGbWA8croFX6Rfg_4D1A3r5-F_59mKyJopVqZMvuFOEng |
| CitedBy_id | crossref_primary_10_54101_ACEN_2023_4_1 crossref_primary_10_1155_2023_2305163 crossref_primary_10_1136_bcr_2020_238519 crossref_primary_10_1111_dmcn_15493 crossref_primary_10_1186_s12883_025_04312_3 crossref_primary_10_3389_fneur_2021_653734 crossref_primary_10_1016_j_banm_2021_07_004 crossref_primary_10_3389_fnhum_2024_1405617 crossref_primary_10_1136_bmjopen_2023_083669 crossref_primary_10_1002_pds_70123 crossref_primary_10_1016_j_xhgg_2024_100317 crossref_primary_10_1002_acn3_51357 crossref_primary_10_1016_j_jlr_2025_100903 crossref_primary_10_12998_wjcc_v10_i13_4294 crossref_primary_10_1016_j_vaccine_2021_05_016 crossref_primary_10_1080_14737167_2022_2000862 crossref_primary_10_1002_acn3_70137 crossref_primary_10_1016_S1474_4422_19_30144_9 crossref_primary_10_17650_2222_8721_2020_10_2_22_30 crossref_primary_10_1007_s00415_024_12548_1 crossref_primary_10_33262_anatomiadigital_v7i3_3_3180 crossref_primary_10_1002_mus_27235 crossref_primary_10_1016_j_revmed_2021_03_008 crossref_primary_10_1186_s41983_022_00531_4 crossref_primary_10_1080_14737175_2022_2169134 crossref_primary_10_1016_j_autrev_2020_102646 crossref_primary_10_1007_s10072_022_06215_4 crossref_primary_10_1097_WCO_0000000000000727 crossref_primary_10_1111_jns_12551 crossref_primary_10_1212_WNL_0000000000010369 crossref_primary_10_2147_TCRM_S360249 crossref_primary_10_1111_jns_12399 crossref_primary_10_1016_j_ncl_2020_03_008 crossref_primary_10_1016_j_cger_2021_01_006 crossref_primary_10_1186_s12984_024_01518_3 crossref_primary_10_1016_j_ejrad_2020_109164 crossref_primary_10_1002_14651858_CD001797_pub4 crossref_primary_10_1007_s12328_020_01281_7 crossref_primary_10_46518_kjnmd_2022_14_1_1 crossref_primary_10_1016_j_neurol_2023_03_010 crossref_primary_10_1080_13543784_2024_2394186 crossref_primary_10_1177_22143602241313118 crossref_primary_10_3389_fnmol_2021_779385 crossref_primary_10_1212_NXI_0000000000200162 crossref_primary_10_1016_j_jad_2025_120204 crossref_primary_10_1111_imj_15694 crossref_primary_10_1038_s41598_020_73104_1 crossref_primary_10_1136_jnnp_2022_329633 crossref_primary_10_1186_s12974_021_02113_2 crossref_primary_10_3390_neurolint15010027 crossref_primary_10_3390_jcm10143016 crossref_primary_10_3390_biomedicines9040399 crossref_primary_10_1016_j_ejpn_2024_09_005 crossref_primary_10_1055_s_0045_1805073 crossref_primary_10_1007_s40120_025_00732_y crossref_primary_10_1016_j_nmd_2024_07_006 crossref_primary_10_7759_cureus_19041 crossref_primary_10_1093_brain_awaa265 crossref_primary_10_1186_s12882_024_03830_5 crossref_primary_10_1016_j_neurol_2022_06_004 crossref_primary_10_1212_CON_0000000000000907 crossref_primary_10_1016_j_jocn_2020_02_009 crossref_primary_10_3389_fimmu_2025_1575464 crossref_primary_10_1097_MPG_0000000000002654 crossref_primary_10_1007_s00415_020_10287_7 crossref_primary_10_1007_s13311_021_01117_3 crossref_primary_10_1016_j_msard_2020_101943 crossref_primary_10_1186_s12883_022_02816_w crossref_primary_10_3390_brainsci11020202 crossref_primary_10_1007_s00415_020_09998_8 crossref_primary_10_1136_jnnp_2023_333112 crossref_primary_10_3389_fnhum_2023_1229440 crossref_primary_10_2147_JIR_S224781 crossref_primary_10_1002_mus_27046 crossref_primary_10_3389_fimmu_2022_1038411 crossref_primary_10_1016_j_jep_2024_118137 crossref_primary_10_1136_jnnp_2020_322971 crossref_primary_10_1080_21645515_2022_2159215 crossref_primary_10_1007_s00415_021_10677_5 crossref_primary_10_14309_crj_0000000000000993 crossref_primary_10_1007_s00415_025_13208_8 crossref_primary_10_1111_ene_16399 crossref_primary_10_1186_s13578_023_00956_1 crossref_primary_10_3389_fimmu_2024_1346671 crossref_primary_10_1007_s00415_024_12812_4 crossref_primary_10_1097_NAN_0000000000000581 crossref_primary_10_1007_s40120_023_00479_4 crossref_primary_10_1371_journal_pone_0228679 crossref_primary_10_2174_011573398X278492231228094147 crossref_primary_10_3390_ph15050607 crossref_primary_10_1136_pn_2022_003655 crossref_primary_10_7759_cureus_44361 crossref_primary_10_1007_s40120_023_00512_6 crossref_primary_10_1007_s00415_024_12456_4 crossref_primary_10_1016_j_autrev_2022_103032 crossref_primary_10_1186_s12883_023_03223_5 crossref_primary_10_1055_s_0045_1809884 crossref_primary_10_1016_j_clinthera_2022_06_008 crossref_primary_10_3390_jcm13123604 crossref_primary_10_17116_jnevro202412402158 crossref_primary_10_1002_ccr3_9217 crossref_primary_10_3389_fimmu_2022_890142 crossref_primary_10_1007_s10072_021_05811_0 crossref_primary_10_1111_jns_12344 crossref_primary_10_1111_jns_12502 crossref_primary_10_1016_j_clinph_2021_05_018 crossref_primary_10_3389_fphar_2024_1420682 crossref_primary_10_1097_NAN_0000000000000441 crossref_primary_10_1111_ene_14796 crossref_primary_10_1111_ene_14950 crossref_primary_10_3389_fimmu_2021_686466 crossref_primary_10_1080_14737175_2022_2036125 crossref_primary_10_7759_cureus_76749 crossref_primary_10_1001_jamadermatol_2020_0055 crossref_primary_10_1002_acn3_51061 crossref_primary_10_1186_s12984_025_01685_x crossref_primary_10_1002_mus_27698 crossref_primary_10_1007_s10072_020_04588_y |
| ContentType | Journal Article |
| Copyright | 2019 The Author(s) Published by S. Karger AG, Basel 2019 The Author(s) Published by S. Karger AG, Basel. |
| Copyright_xml | – notice: 2019 The Author(s) Published by S. Karger AG, Basel – notice: 2019 The Author(s) Published by S. Karger AG, Basel. |
| DBID | M-- CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1159/000494291 |
| DatabaseName | Karger Open Access Journals Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: M-- name: Karger Open Access Journals url: https://www.karger.com/OpenAccess sourceTypes: Enrichment Source Publisher – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1423-0208 |
| EndPage | 172 |
| ExternalDocumentID | 30669140 494291 |
| Genre | Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review Journal Article |
| GroupedDBID | --- 0R~ 0~5 0~B 123 29N 30W 325 36B 3O. 3V. 4.4 53G 5RE 7X7 88E 88I 8AF 8AO 8C1 8FI 8FJ 8UI AAYIC ABIVO ABJNI ABPAZ ABUWG ACGFS ACGOD ACPRK ACPSR ADAGL ADBBV ADGES AENEX AEYAO AFJJK AFKRA AFRAH AHMBA ALDHI ALIPV ALMA_UNASSIGNED_HOLDINGS AZPMC AZQEC BENPR BPHCQ BVXVI CAG CCPQU COF CS3 CYUIP DU5 DWQXO E0A EBS EJD EMOBN F5P FB. FYUFA GNUQQ HCIFZ HMCUK HZ~ IAO IHR IHW IY7 KUZGX M-- M1P M2M M2P N9A O1H O9- P2P PQQKQ PROAC PSQYO PSYQQ RIG RKO RXVBD S0X UJ6 UKHRP YHZ ZGI ABBTS ABWCG ACQXL AFSIO AHFRZ CGR CUY CVF ECM EIF ITC NPM 7X8 |
| ID | FETCH-LOGICAL-c522t-94c21fb837a4282b99d0f4d35c7741fcf64a5484ec67e8fc221451e5d4e8646e3 |
| IEDL.DBID | M-- |
| ISICitedReferencesCount | 126 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000466136400006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0251-5350 1423-0208 |
| IngestDate | Thu Sep 04 18:32:10 EDT 2025 Wed Feb 19 02:30:45 EST 2025 Thu Aug 29 12:04:29 EDT 2024 Thu Sep 05 19:48:36 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3-4 |
| Keywords | Systematic review Prevalence Chronic inflammatory demyelinating polyradiculoneuropathy Incidence Meta-analysis |
| Language | English |
| License | This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. 2019 The Author(s) Published by S. Karger AG, Basel. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c522t-94c21fb837a4282b99d0f4d35c7741fcf64a5484ec67e8fc221451e5d4e8646e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://karger.com/doi/10.1159/000494291 |
| PMID | 30669140 |
| PQID | 2179407208 |
| PQPubID | 23479 |
| PageCount | 12 |
| ParticipantIDs | karger_primary_494291 proquest_miscellaneous_2179407208 pubmed_primary_30669140 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-01-01 |
| PublicationDateYYYYMMDD | 2019-01-01 |
| PublicationDate_xml | – month: 01 year: 2019 text: 2019-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Basel, Switzerland |
| PublicationPlace_xml | – name: Basel, Switzerland – name: Switzerland |
| PublicationTitle | Neuroepidemiology |
| PublicationTitleAlternate | Neuroepidemiology |
| PublicationYear | 2019 |
| References | Viechtbauer W: Conducting meta-analyses in R with the metafor package. J Stat Software 2010; 36: 1–48. Stijnen et al: (2010). http://www.metafor-project.org/doku.php/analyses:stijnen2010 (cited July 31, 2017). Hanewinckel R, van Oijen M, Ikram MA, van Doorn PA: The epidemiology and risk factors of chronic polyneuropathy. Eur J Epidemiol 2016; 31: 5–20. Iijima M, Koike H, Hattori N, Tamakoshi A, Katsuno M, Tanaka F, Yamamoto M, Arimura K, Sobue G; Refractory Peripheral Neuropathy Study Group of Japan: Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population. J Neurol Neurosurg Psychiatry 2008; 79: 1040–1043. Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV: Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975; 50: 621–637. Vlam L, van der Pol WL, Cats EA, Straver DC, Piepers S, Franssen H, van den Berg LH: Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nat Rev Neurol 2011; 8: 48–58. Manfredini D, Restrepo C, Diaz-Serrano K, Winocur E, Lobbezoo F: Prevalence of sleep bruxism in children: a systematic review of the literature. J Oral Rehabil 2013; 40: 631–642. Leonhard SE, Munts AG, van der Eijk AA, Jacobs BC: Acute-onset chronic inflammatory demyelinating polyneuropathy after Zika virus infection. J Neurol Neurosurg Psychiatry 2018; 89: 1118–1119. Vallat JM, Sommer C, Magy L: Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. Lancet Neurol 2010; 9: 402–412. Rajabally YA, Nicolas G, Pieret F, Bouche P, Van den Bergh PY: Validity of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy: a multicentre European study. J Neurol Neurosurg Psychiatry 2009; 80: 1364–1368. McLeod JG, Pollard JD, Macaskill P, Mohamed A, Spring P, Khurana V: Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol 1999; 46: 910–913. Cats EA, van der Pol WL, Piepers S, Franssen H, Jacobs BC, van den Berg-Vos RM, Kuks JB, van Doorn PA, van Engelen BG, Verschuuren JJ, Wokke JH, Veldink JH, van den Berg LH: Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology 2010; 75: 818–825. Breiner A, Brannagan TH 3rd: Comparison of sensitivity and specificity among 15 criteria for chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2014; 50: 40–46. Saperstein DS, Katz JS, Amato AA, Barohn RJ: Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001; 24: 311–324. Gorson KC, Allam G, Ropper AH: Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997; 48: 321–328. Prevalence and Incidence of Rare Diseases: Bibliographic Data, O.R. Series, Editor, 2017. Rajabally YA, Simpson BS, Beri S, Bankart J, Gosalakkal JA: Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population. Muscle Nerve 2009; 39: 432–438. Brazinova A, Rehorcikova V, Taylor MS, Buckova V, Majdan M, Psota M, Peeters W, Feigin V, Theadom A, Holkovic L, Synnot A: Epidemiology of traumatic brain injury in Europe: a living systematic review. J Neurotrauma 2016, Epub ahead of print. Hafsteinsdottir B, Olafsson E: Incidence and natural history of idiopathic chronic inflammatory demyelinating polyneuropathy: a population-based study in Iceland. Eur Neurol 2016; 75: 263–268. Laughlin RS, Dyck PJ, Melton LJ 3rd, Leibson C, Ransom J, Dyck PJ: Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology 2009; 73: 39–45. Albers JW, Kelly JJ Jr: Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features. Muscle Nerve 1989; 12: 435–451. Bril V, Blanchette CM, Noone JM, Runken MC, Gelinas D, Russell JW: The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy. J Diabetes Complications 2016; 30: 1401–1407. Hughes R, Bensa S, Willison H, Van den Bergh P, Comi G, Illa I, Nobile-Orazio E, van Doorn P, Dalakas M, Bojar M, Swan A; Inflammatory Neuropathy Cause and Treatment (INCAT) Group: Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001; 50: 195–201. Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W: The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford) 2017; 56: 1945–1961. da Silva IRF, Frontera JA, Bispo de Filippis AM, Nascimento OJMD; RIO-GBS-ZIKV Research Group: Neurologic complications associated With the Zika Virus in Brazilian adults. JAMA Neurol 2017; 74: 1190–1198. Hughes RA, Bouche P, Cornblath DR, Evers E, Hadden RD, Hahn A, Illa I, Koski CL, Leger JM, Nobile-Orazio E, Pollard J, Sommer C, Van den Bergh P, van Doorn PA, van Schaik IN: European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2006; 13: 326–332. Kayser SC, Dekkers T, Groenewoud HJ, van der Wilt GJ, Carel Bakx J, van der Wel MC, Hermus AR, Lenders JW, Deinum J: Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis. J Clin Endocrinol Metab 2016; 101: 2826–2835. Tackenberg B, Lunemann JD, Steinbrecher A, Rothenfusser-Korber E, Sailer M, Bruck W, Schock S, Zschenderlein R, Zipp F, Sommer N: Classifications and treatment responses in chronic immune-mediated demyelinating polyneuropathy. Neurology 2007; 68: 1622–1629. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 1991; 41: 617–618. Sejvar JJ, Baughman AL, Wise M, Morgan OW: Population incidence of Guillain-Barre syndrome: a systematic review and meta-analysis. Neuroepidemiology 2011; 36: 123–133. Gorson KC, van Schaik IN, Merkies IS, Lewis RA, Barohn RJ, Koski CL, Cornblath DR, Hughes RA, Hahn AF, Baumgarten M, Goldstein J, Katz J, Graves M, Parry G, van Doorn PA: Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice. J Peripher Nerv Syst 2010; 15: 326–333. Trojano M, Lucchese G, Graziano G, Taylor BV, Simpson S Jr, Lepore V, Grand'maison F, Duquette P, Izquierdo G, Grammond P, Amato MP, Bergamaschi R, Giuliani G, Boz C, Hupperts R, Van Pesch V, Lechner-Scott J, Cristiano E, Fiol M, Oreja-Guevara C, Saladino ML, Verheul F, Slee M, Paolicelli D, Tortorella C, D'Onghia M, Iaffaldano P, Direnzo V, Butzkueven H; MSBase Study Group and the New Zealand MS Prevalence Study Group: Geographical variations in sex ratio trends over time in multiple sclerosis. PLoS One 2012; 7:e48078. Mygland A, Monstad P: Chronic polyneuropathies in Vest-Agder, Norway. Eur J Neurol 2001; 8: 157–165. Patel R, Shahane A: The epidemiology of Sjogren’s syndrome. Clin Epidemiol 2014; 6: 247–255. Edmondson D, Richardson S, Fausett JK, Falzon L, Howard VJ, Kronish IM: Prevalence of PTSD in survivors of stroke and transient ischemic attack: a meta-analytic review. PLoS One 2013; 8:e66435. Koller H, Kieseier BC, Jander S, Hartung HP: Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005; 352: 1343–1356. Manfredini D, Winocur E, Guarda-Nardini L, Paesani D, Lobbezoo F: Epidemiology of bruxism in adults: a systematic review of the literature. J Orofac Pain 2013; 27: 99–110. Nobile-Orazio E: Chronic inflammatory demyelinating polyradiculoneuropathy and variants: where we are and where we should go. J Peripher Nerv Syst 2014; 19: 2–13. Lefter S, Hardiman O, Ryan AM: A population-based epidemiologic study of adult neuromuscular disease in the Republic of Ireland. Neurology 2017; 88: 304–313. Rudolph T, Farbu E: Hospital-referred polyneuropathies–causes, prevalences, clinical- and neurophysiological findings. Eur J Neurol 2007; 14: 603–608. Shamliyan TA, Kane RL, Ansari MT, Raman G, Berkman ND, Grant M, Janes G, Maglione M, Moher D, Nasser M, Robinson KA, Segal JB, Tsouros S: Development quality criteria to evaluate nontherapeutic studies of incidence, prevalence, or risk factors of chronic diseases: pilot study of new checklists. J Clin Epidemiol 2011; 64: 637–657. Willison HJ, Jacobs BC, van Doorn PA: Guillain-Barre syndrome. Lancet 2016; 388: 717–727. Kusumi M, Nakashima K, Nakayama H, Takahashi K: Epidemiology of inflammatory neurological and inflammatory neuromuscular diseases in Tottori Prefecture, Japan. Psychiatry Clin Neurosci 1995; 49: 169–174. Mahdi-Rogers M, Hughes RA: Epidemiology of chronic inflammatory neuropathies in southeast England. Eur J Neurol 2014; 21: 28–33. Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A: Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis 2015; 74: 65–73. Miller (1978). http://www.metafor-project.org/doku.php/analyses:miller1978 [cited July 31, 2017]. Sander HW, Latov N: Research criteria for defining patients with CIDP. Neurology 2003; 60(8 suppl 3):S8–S15. Bromberg MB: Review of the evolution of electrodiagnostic criteria for chronic inflammatory demyelinating polyradicoloneuropathy. Muscle Nerve 2011; 43: 780–794. Callan A, Capkun G, Vasanthaprasad V, Freitas R, Needham M: A systematic review and meta-analysis of prevalence studies of sporadic inclusion body myositis. J Neuromuscul Dis 2017; 4: 127–137. Deenen JC, Horlings CG, Verschuuren JJ, Verbeek AL, van Engelen BG: The epidemiology of neuromuscular disorders: a comprehensive overview of the literature. J Neuromuscul Dis 2015; 2: 73–85. Chi |
| References_xml | – reference: Chio A, Cocito D, Bottacchi E, Buffa C, Leone M, Plano F, Mutani R, Calvo A; PARCIDP: Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. J Neurol Neurosurg Psychiatry 2007; 78: 1349–1353. – reference: Gorson KC, Allam G, Ropper AH: Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997; 48: 321–328. – reference: Manfredini D, Winocur E, Guarda-Nardini L, Paesani D, Lobbezoo F: Epidemiology of bruxism in adults: a systematic review of the literature. J Orofac Pain 2013; 27: 99–110. – reference: Albers JW, Kelly JJ Jr: Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features. Muscle Nerve 1989; 12: 435–451. – reference: Viechtbauer W: Conducting meta-analyses in R with the metafor package. J Stat Software 2010; 36: 1–48. – reference: Patel R, Shahane A: The epidemiology of Sjogren’s syndrome. Clin Epidemiol 2014; 6: 247–255. – reference: Rajabally YA, Nicolas G, Pieret F, Bouche P, Van den Bergh PY: Validity of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy: a multicentre European study. J Neurol Neurosurg Psychiatry 2009; 80: 1364–1368. – reference: McLeod JG, Pollard JD, Macaskill P, Mohamed A, Spring P, Khurana V: Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol 1999; 46: 910–913. – reference: Trojano M, Lucchese G, Graziano G, Taylor BV, Simpson S Jr, Lepore V, Grand'maison F, Duquette P, Izquierdo G, Grammond P, Amato MP, Bergamaschi R, Giuliani G, Boz C, Hupperts R, Van Pesch V, Lechner-Scott J, Cristiano E, Fiol M, Oreja-Guevara C, Saladino ML, Verheul F, Slee M, Paolicelli D, Tortorella C, D'Onghia M, Iaffaldano P, Direnzo V, Butzkueven H; MSBase Study Group and the New Zealand MS Prevalence Study Group: Geographical variations in sex ratio trends over time in multiple sclerosis. PLoS One 2012; 7:e48078. – reference: Rudolph T, Farbu E: Hospital-referred polyneuropathies–causes, prevalences, clinical- and neurophysiological findings. Eur J Neurol 2007; 14: 603–608. – reference: PRISMA Preferred Reporting Items of Systematic Reviews and Meta-Analyses. http://www.prisma-statement.org/ (cited 2017). – reference: Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W: The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford) 2017; 56: 1945–1961. – reference: Koller H, Kieseier BC, Jander S, Hartung HP: Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005; 352: 1343–1356. – reference: Bromberg MB: Review of the evolution of electrodiagnostic criteria for chronic inflammatory demyelinating polyradicoloneuropathy. Muscle Nerve 2011; 43: 780–794. – reference: Edmondson D, Richardson S, Fausett JK, Falzon L, Howard VJ, Kronish IM: Prevalence of PTSD in survivors of stroke and transient ischemic attack: a meta-analytic review. PLoS One 2013; 8:e66435. – reference: Oaklander AL, Lunn MP, Hughes RA, van Schaik IN, Frost C, Chalk CH: Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane Database Syst Rev 2017; 1:CD010369. – reference: Callan A, Capkun G, Vasanthaprasad V, Freitas R, Needham M: A systematic review and meta-analysis of prevalence studies of sporadic inclusion body myositis. J Neuromuscul Dis 2017; 4: 127–137. – reference: Deenen JC, Horlings CG, Verschuuren JJ, Verbeek AL, van Engelen BG: The epidemiology of neuromuscular disorders: a comprehensive overview of the literature. J Neuromuscul Dis 2015; 2: 73–85. – reference: Willison HJ, Jacobs BC, van Doorn PA: Guillain-Barre syndrome. Lancet 2016; 388: 717–727. – reference: Hanewinckel R, van Oijen M, Ikram MA, van Doorn PA: The epidemiology and risk factors of chronic polyneuropathy. Eur J Epidemiol 2016; 31: 5–20. – reference: Lunn MP, Manji H, Choudhary PP, Hughes RA, Thomas PK: Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry 1999; 66: 677–680. – reference: Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV: Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975; 50: 621–637. – reference: PROSPERO International Prospective Register of Systematic Reviews. https://www.crd.york.ac.uk/PROSPERO/ (cited 2017). – reference: Sejvar JJ, Baughman AL, Wise M, Morgan OW: Population incidence of Guillain-Barre syndrome: a systematic review and meta-analysis. Neuroepidemiology 2011; 36: 123–133. – reference: Mahdi-Rogers M, Hughes RA: Epidemiology of chronic inflammatory neuropathies in southeast England. Eur J Neurol 2014; 21: 28–33. – reference: Hughes R, Bensa S, Willison H, Van den Bergh P, Comi G, Illa I, Nobile-Orazio E, van Doorn P, Dalakas M, Bojar M, Swan A; Inflammatory Neuropathy Cause and Treatment (INCAT) Group: Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001; 50: 195–201. – reference: Shamliyan TA, Kane RL, Ansari MT, Raman G, Berkman ND, Grant M, Janes G, Maglione M, Moher D, Nasser M, Robinson KA, Segal JB, Tsouros S: Development quality criteria to evaluate nontherapeutic studies of incidence, prevalence, or risk factors of chronic diseases: pilot study of new checklists. J Clin Epidemiol 2011; 64: 637–657. – reference: Stijnen et al: (2010). http://www.metafor-project.org/doku.php/analyses:stijnen2010 (cited July 31, 2017). – reference: Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 1991; 41: 617–618. – reference: Gorson KC, van Schaik IN, Merkies IS, Lewis RA, Barohn RJ, Koski CL, Cornblath DR, Hughes RA, Hahn AF, Baumgarten M, Goldstein J, Katz J, Graves M, Parry G, van Doorn PA: Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice. J Peripher Nerv Syst 2010; 15: 326–333. – reference: Kusumi M, Nakashima K, Nakayama H, Takahashi K: Epidemiology of inflammatory neurological and inflammatory neuromuscular diseases in Tottori Prefecture, Japan. Psychiatry Clin Neurosci 1995; 49: 169–174. – reference: Hughes RA, Bouche P, Cornblath DR, Evers E, Hadden RD, Hahn A, Illa I, Koski CL, Leger JM, Nobile-Orazio E, Pollard J, Sommer C, Van den Bergh P, van Doorn PA, van Schaik IN: European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2006; 13: 326–332. – reference: Kuitwaard K, Bos-Eyssen ME, Blomkwist-Markens PH, van Doorn PA: Recurrences, vaccinations and long-term symptoms in GBS and CIDP. J Peripher Nerv Syst 2009; 14: 310–315. – reference: Mygland A, Monstad P: Chronic polyneuropathies in Vest-Agder, Norway. Eur J Neurol 2001; 8: 157–165. – reference: Dyck PJ, Thomas PK, Griffin JW, editors. Peripheral Neuropathy, ed 3. Philadelphia, WB Saunders, 1993. – reference: Vlam L, van der Pol WL, Cats EA, Straver DC, Piepers S, Franssen H, van den Berg LH: Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nat Rev Neurol 2011; 8: 48–58. – reference: Nobile-Orazio E: Chronic inflammatory demyelinating polyradiculoneuropathy and variants: where we are and where we should go. J Peripher Nerv Syst 2014; 19: 2–13. – reference: Albulaihe H, Alabdali M, Alsulaiman A, Abraham A, Breiner A, Barnett C, Katzberg HD, Lovblom LE, Perkins BA, Bril V: Disease activity in chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2016; 369: 204–209. – reference: Iijima M, Koike H, Hattori N, Tamakoshi A, Katsuno M, Tanaka F, Yamamoto M, Arimura K, Sobue G; Refractory Peripheral Neuropathy Study Group of Japan: Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population. J Neurol Neurosurg Psychiatry 2008; 79: 1040–1043. – reference: Brazinova A, Rehorcikova V, Taylor MS, Buckova V, Majdan M, Psota M, Peeters W, Feigin V, Theadom A, Holkovic L, Synnot A: Epidemiology of traumatic brain injury in Europe: a living systematic review. J Neurotrauma 2016, Epub ahead of print. – reference: Cats EA, van der Pol WL, Piepers S, Franssen H, Jacobs BC, van den Berg-Vos RM, Kuks JB, van Doorn PA, van Engelen BG, Verschuuren JJ, Wokke JH, Veldink JH, van den Berg LH: Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology 2010; 75: 818–825. – reference: Sander HW, Latov N: Research criteria for defining patients with CIDP. Neurology 2003; 60(8 suppl 3):S8–S15. – reference: Laughlin RS, Dyck PJ, Melton LJ 3rd, Leibson C, Ransom J, Dyck PJ: Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology 2009; 73: 39–45. – reference: Prevalence and Incidence of Rare Diseases: Bibliographic Data, O.R. Series, Editor, 2017. – reference: Breiner A, Brannagan TH 3rd: Comparison of sensitivity and specificity among 15 criteria for chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2014; 50: 40–46. – reference: Leonhard SE, Munts AG, van der Eijk AA, Jacobs BC: Acute-onset chronic inflammatory demyelinating polyneuropathy after Zika virus infection. J Neurol Neurosurg Psychiatry 2018; 89: 1118–1119. – reference: Kandil MR, Darwish ES, Khedr EM, Sabry MM, Abdulah MA: A community-based epidemiological study of peripheral neuropathies in Assiut, Egypt. Neurol Res 2012; 34: 960–966. – reference: Rajabally YA, Simpson BS, Beri S, Bankart J, Gosalakkal JA: Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population. Muscle Nerve 2009; 39: 432–438. – reference: Manfredini D, Restrepo C, Diaz-Serrano K, Winocur E, Lobbezoo F: Prevalence of sleep bruxism in children: a systematic review of the literature. J Oral Rehabil 2013; 40: 631–642. – reference: Miller (1978). http://www.metafor-project.org/doku.php/analyses:miller1978 [cited July 31, 2017]. – reference: Joint Task Force of the EFNS and the PNS: European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society – First Revision. J Peripher Nerv Syst 2010; 15: 1–9. – reference: Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A: Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis 2015; 74: 65–73. – reference: McCombe PA, Pollard JD, McLeod JG: Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain 1987; 110(Pt 6): 1617–1630. – reference: Deenen JC, van Doorn PA, Faber CG, van der Kooi AJ, Kuks JB, Notermans NC, Visser LH, Horlings CG, Verschuuren JJ, Verbeek AL, van Engelen BG: The epidemiology of neuromuscular disorders: age at onset and gender in the Netherlands. Neuromuscul Disord 2016; 26: 447–452. – reference: da Silva IRF, Frontera JA, Bispo de Filippis AM, Nascimento OJMD; RIO-GBS-ZIKV Research Group: Neurologic complications associated With the Zika Virus in Brazilian adults. JAMA Neurol 2017; 74: 1190–1198. – reference: Vallat JM, Sommer C, Magy L: Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. Lancet Neurol 2010; 9: 402–412. – reference: Lefter S, Hardiman O, Ryan AM: A population-based epidemiologic study of adult neuromuscular disease in the Republic of Ireland. Neurology 2017; 88: 304–313. – reference: Visser NA, Notermans NC, Linssen RS, van den Berg LH, Vrancken AF: Incidence of polyneuropathy in Utrecht, the Netherlands. Neurology 2015; 84: 259–264. – reference: Tackenberg B, Lunemann JD, Steinbrecher A, Rothenfusser-Korber E, Sailer M, Bruck W, Schock S, Zschenderlein R, Zipp F, Sommer N: Classifications and treatment responses in chronic immune-mediated demyelinating polyneuropathy. Neurology 2007; 68: 1622–1629. – reference: Bril V, Blanchette CM, Noone JM, Runken MC, Gelinas D, Russell JW: The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy. J Diabetes Complications 2016; 30: 1401–1407. – reference: Saperstein DS, Katz JS, Amato AA, Barohn RJ: Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001; 24: 311–324. – reference: Guptill JT, Bromberg MB, Zhu L, Sharma BK, Thompson AR, Krueger A, Sanders DB: Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2014; 50: 47–51. – reference: Hafsteinsdottir B, Olafsson E: Incidence and natural history of idiopathic chronic inflammatory demyelinating polyneuropathy: a population-based study in Iceland. Eur Neurol 2016; 75: 263–268. – reference: Kayser SC, Dekkers T, Groenewoud HJ, van der Wilt GJ, Carel Bakx J, van der Wel MC, Hermus AR, Lenders JW, Deinum J: Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis. J Clin Endocrinol Metab 2016; 101: 2826–2835. |
| SSID | ssj0015989 |
| Score | 2.5544357 |
| SecondaryResourceType | review_article |
| Snippet | Background: Prevalence and incidence rates of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) are required to determine the impact of CIDP on... Prevalence and incidence rates of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) are required to determine the impact of CIDP on society. We... |
| SourceID | proquest pubmed karger |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 161 |
| SubjectTerms | Humans Incidence Observational Studies as Topic - methods Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - diagnosis Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - epidemiology Prevalence Systematic Review |
| Title | Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis |
| URI | https://karger.com/doi/10.1159/000494291 https://www.ncbi.nlm.nih.gov/pubmed/30669140 https://www.proquest.com/docview/2179407208 |
| Volume | 52 |
| WOSCitedRecordID | wos000466136400006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3da9swED_WrJTC6Ge2ps2CCnsVtS1ZtvZW1pbuISHQDfJmZH1AaeOENBkE9sf3JDmBDQp98YONfEJ3kn660_0O4JszuRJGGJo5wShPDc45YSU1OtNCSWkTo0KxiWI0KicTOW79HT4X5snffw7UqFtuAdxwryKPSebT1D_ihpv6Ig1DSrfxglyGYnceMNOc5UnLIfRP033YQ3wsZOodHbtR0Nu4Muwvd4fv79kRHLQYklxHpR_DB9ucwN6wjZKfwKfoiyMxxegU_uIiEGuHEtUY4lmbVMg1IjNHWnZc8rNxaBzTEHQnN3a69onqyl-KJuPZ83qhjPcUzgL_pS9jvP5OrsnDlgeaxCBDEDC0S0U3bCdd-H13--vHPW2rLlCNWGxJJddZ6mo8uCo8mmS1lCZx3LBcI1JMnXaCKzzmcKtFYUunM891ntrccFsKLiz7DJ0Ge3MGhDOLhsBq1L7jqpCKpXXtakQFhrmU5T3oxlGt5pFao4pD2YP-f-9HtzfxUzU3rgeXG6VVOBl8hEM1drZ6qTK_vCRFlpQ9-BK1uf3FRvfnbwi9gH0EQzK6V_rQWS5W9ivs6j_Lx5fFAHaKSTkIRofP0Xj4CsqY0R0 |
| linkProvider | Karger AG |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1ZS8QwEB5ERQXxPtYzgq_BtknTjW_igaK7CCr4VtIcIGpX1lVY8Mc7SboLCoKvLW3CTI5vrm8ADp3JlTDC0MwJRnlqcM8JK6nRmRZKSpsYFZpNFN1u-_FR3jb-Dl8L8-zznwM16phbAC_co8hjkvky9alCImbwSXqUjuMFuQzN7jxgpjnLk4ZD6MenczCD-FjI1Ds6puNAf-PKcL9cLP5_Zkuw0GBIchKVvgwTtl6BmU4TJV-B-eiLI7HEaBW-8BCIvUOJqg3xrE0q1BqRniMNOy65qh0ujtcQdCdn9nXoC9WVT4omt72XYV8Z7ynsBf5L38Z4eExOyN2YB5rEIEMYoGMHio7YTtbg4eL8_vSSNl0XqEa5DqjkOktdhYarQtMkq6Q0ieOG5RqRYuq0E1yhmcOtFoVtO515rvPU5obbtuDCsnWYrHE2m0A4s7gQWIXad1wVUrG0qlyFqMAwl7K8BWtRquVbpNYooyhbsPPreff8LL4q34xrwcFIaSVuBh_hULXtfbyXmT9ekiJL2i3YiNoc_2Kk-60_Bt2H2cv7zk15c9W93oY5BEYyulp2YHLQ_7C7MK0_B0_v_b2w9L4B-fvSHw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Incidence+and+Prevalence+of+Chronic+Inflammatory+Demyelinating+Polyradiculoneuropathy%3A+A+Systematic+Review+and+Meta-Analysis&rft.jtitle=Neuroepidemiology&rft.au=Broers%2C+Merel%C2%A0C.&rft.au=Bunschoten%2C+Carina&rft.au=Nieboer%2C+Daan&rft.au=Lingsma%2C+Hester%C2%A0F.&rft.date=2019-01-01&rft.issn=0251-5350&rft.eissn=1423-0208&rft.volume=52&rft.issue=3-4&rft.spage=161&rft.epage=172&rft_id=info:doi/10.1159%2F000494291&rft_id=info%3Apmid%2F30669140&rft.externalDocID=494291 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0251-5350&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0251-5350&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0251-5350&client=summon |